Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers

Authors: Ki Hyung Kim, Moo Sung Jo, Dong Soo Suh, Man Soo Yoon, Dong Hun Shin, Jeong Hee Lee, Kyung Un Choi

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

Toll-like receptors (TLR) are a family of pattern recognition receptors that constitutes a major part of the innate immune system. The TLR4/(Myeloid differentiation factor 88 (MyD88) signaling pathway has been shown to have oncogenic effects.

Methods

To demonstrate the role of TLR4/MyD88 signaling in ovarian epithelial cancers (OECs), we examined the expression of TLR4, MyD88 and nuclear factor- κB (NF-κB) in OECs. The expression of TLR4, MyD88, and NF-κB was detected by immunohistochemistry, and the relationships between these and clinicopathologic features in 123 cases of OECs were also analyzed.

Results

The expression of TLR4, MyD88, and NF-κB in OECs was observed in 46.3% (57/123), 36.6% (45/123) and 65% (80/123) of OEC cases, respectively. The TLR4, MyD88, and NF-κB expressions were associated with the histologic type of OECs, particularly with the clear cell type of OEC. There was no significant correlation between TLR4 or NF-κB expression and histologic grade, tumor size, mitotic count, FIGO (International Federation of Gynecology and Obstetrics) stage, disease recurrence. However, there was a significant correlation between MyD88 expression and FIGO stage, disease recurrence as well as histologic type. In univariate analysis, the expression of TLR4 and MyD88, and the coexpression of TLR4/MyD88 and TLR4/MyD88/NF-κB had a significant impact on the survival of patients with OECs. Only MyD88 expression had an independent prognostic significance in multivariate analysis.

Conclusions

Our findings suggest that the TLR4/MyD88 signaling pathway is associated with the survival of patients with OECs, and that MyD88 is an independent prognostic predictor in patients with OECs. The TLR4/MyD88 signaling pathway may be a mechanism responsible for poor prognosis in patients with clear cell type of OEC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yu L, Chen S: Toll-like receptors expressed in tumor cells: Targets for therapy. Cancer Immunol Immunother. 2008, 57: 1271-1278. 10.1007/s00262-008-0459-8.CrossRefPubMed Yu L, Chen S: Toll-like receptors expressed in tumor cells: Targets for therapy. Cancer Immunol Immunother. 2008, 57: 1271-1278. 10.1007/s00262-008-0459-8.CrossRefPubMed
2.
go back to reference Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H: TLR signaling by tumor and immune cells: A double-edged sword. Oncogene. 2008, 27: 218-224. 10.1038/sj.onc.1210904.CrossRefPubMed Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H: TLR signaling by tumor and immune cells: A double-edged sword. Oncogene. 2008, 27: 218-224. 10.1038/sj.onc.1210904.CrossRefPubMed
3.
go back to reference Rakoff-Nahoum S, Medzhitov R: Toll-like receptors and cancer. Nat Rev Cancer. 2009, 9: 57-63. 10.1038/nrc2541.CrossRefPubMed Rakoff-Nahoum S, Medzhitov R: Toll-like receptors and cancer. Nat Rev Cancer. 2009, 9: 57-63. 10.1038/nrc2541.CrossRefPubMed
4.
go back to reference Akira S: Toll-like receptor signaling. J Biol Chem. 2003, 278: 38105-38108. 10.1074/jbc.R300028200.CrossRefPubMed Akira S: Toll-like receptor signaling. J Biol Chem. 2003, 278: 38105-38108. 10.1074/jbc.R300028200.CrossRefPubMed
5.
go back to reference Naugler WE, Sakurai T, Kim S, Maeda S, Kim A, Elsharkawy AM, Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007, 317: 121-124. 10.1126/science.1140485.CrossRefPubMed Naugler WE, Sakurai T, Kim S, Maeda S, Kim A, Elsharkawy AM, Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007, 317: 121-124. 10.1126/science.1140485.CrossRefPubMed
6.
go back to reference Rakoff-Nahoum S, Medzhitov R: Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007, 317: 124-127. 10.1126/science.1140488.CrossRefPubMed Rakoff-Nahoum S, Medzhitov R: Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007, 317: 124-127. 10.1126/science.1140488.CrossRefPubMed
8.
go back to reference Yu L, Wang L, Chen S: Toll-like receptors, inflammation and tumor in the human female reproductive tract. Am J Reprod Immunol. 2009, 62: 1-8. 10.1111/j.1600-0897.2009.00712.x.CrossRefPubMed Yu L, Wang L, Chen S: Toll-like receptors, inflammation and tumor in the human female reproductive tract. Am J Reprod Immunol. 2009, 62: 1-8. 10.1111/j.1600-0897.2009.00712.x.CrossRefPubMed
9.
go back to reference Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006, 66: 3859-3868. 10.1158/0008-5472.CAN-05-3948.CrossRefPubMed Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006, 66: 3859-3868. 10.1158/0008-5472.CAN-05-3948.CrossRefPubMed
10.
go back to reference Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60: 4693-4696.PubMed Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60: 4693-4696.PubMed
11.
go back to reference Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL: Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol. 2010, 16: 2881-2888. 10.3748/wjg.v16.i23.2881.PubMedCentralCrossRefPubMed Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL: Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol. 2010, 16: 2881-2888. 10.3748/wjg.v16.i23.2881.PubMedCentralCrossRefPubMed
12.
go back to reference Cheng I, Plummer SJ, Casey G, Witte JS: Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007, 16: 352-355. 10.1158/1055-9965.EPI-06-0429.CrossRefPubMed Cheng I, Plummer SJ, Casey G, Witte JS: Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007, 16: 352-355. 10.1158/1055-9965.EPI-06-0429.CrossRefPubMed
13.
go back to reference Song C, Chen LZ, Zhang RH, Yu XJ, Zeng YX: Functional variant in the 3'-untranslated region of toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther. 2006, 5: 1285-1291. 10.4161/cbt.5.10.3304.CrossRefPubMed Song C, Chen LZ, Zhang RH, Yu XJ, Zeng YX: Functional variant in the 3'-untranslated region of toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther. 2006, 5: 1285-1291. 10.4161/cbt.5.10.3304.CrossRefPubMed
14.
go back to reference El-Omar EM, Ng MT, Hold GL: Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene. 2008, 27: 244-252. 10.1038/sj.onc.1210912.CrossRefPubMed El-Omar EM, Ng MT, Hold GL: Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene. 2008, 27: 244-252. 10.1038/sj.onc.1210912.CrossRefPubMed
15.
go back to reference Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T: High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 2010, 102: 908-915. 10.1038/sj.bjc.6605558.PubMedCentralCrossRefPubMed Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T: High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 2010, 102: 908-915. 10.1038/sj.bjc.6605558.PubMedCentralCrossRefPubMed
16.
go back to reference Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF: Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009, 58: 1375-1385. 10.1007/s00262-008-0650-y.CrossRefPubMed Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF: Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009, 58: 1375-1385. 10.1007/s00262-008-0650-y.CrossRefPubMed
17.
go back to reference Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000, 88: 2584-2589. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5.CrossRefPubMed Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000, 88: 2584-2589. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5.CrossRefPubMed
18.
go back to reference Itamochi H, Kigawa J, Terakawa N: Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008, 99: 653-658. 10.1111/j.1349-7006.2008.00747.x.CrossRefPubMed Itamochi H, Kigawa J, Terakawa N: Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008, 99: 653-658. 10.1111/j.1349-7006.2008.00747.x.CrossRefPubMed
19.
go back to reference Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res. 2002, 93: 723-728. 10.1111/j.1349-7006.2002.tb01312.x.CrossRefPubMed Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res. 2002, 93: 723-728. 10.1111/j.1349-7006.2002.tb01312.x.CrossRefPubMed
20.
go back to reference Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC: DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the national cancer institute drug screening program. Anticancer Drugs. 2002, 13: 511-519. 10.1097/00001813-200206000-00010.CrossRefPubMed Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC: DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the national cancer institute drug screening program. Anticancer Drugs. 2002, 13: 511-519. 10.1097/00001813-200206000-00010.CrossRefPubMed
21.
go back to reference Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.CrossRefPubMed Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.CrossRefPubMed
22.
go back to reference Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC: Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010, 116: 3276-3284. 10.1002/cncr.25190.PubMedCentralCrossRefPubMed Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC: Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010, 116: 3276-3284. 10.1002/cncr.25190.PubMedCentralCrossRefPubMed
Metadata
Title
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers
Authors
Ki Hyung Kim
Moo Sung Jo
Dong Soo Suh
Man Soo Yoon
Dong Hun Shin
Jeong Hee Lee
Kyung Un Choi
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-193

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue